What are the potential side effects of tigecycline treatment?

What side effects are most common with tigecycline

Nausea and vomiting occur in about 20 percent of patients. Diarrhea is reported in roughly 13 percent, and headache and dizziness appear in 5 to 7 percent. These gastrointestinal effects are dose related and usually appear within the first week of therapy.

What serious adverse events require stopping tigecycline

Acute pancreatitis has been documented in both adults and children. Liver enzyme elevations, including increases in ALT and AST, are seen in up to 6 percent of patients. Rare but life-threatening hypersensitivity reactions, including anaphylaxis, have also been reported.

How does liver toxicity compare with other tetracyclines

Tigecycline carries a boxed warning for increased all-cause mortality, particularly in patients with hospital-acquired pneumonia. Hepatotoxicity rates are higher than with minocycline or doxycycline, and monitoring of liver function tests is recommended at baseline and weekly during therapy.

Can tigecycline cause blood disorders

Transient neutropenia and thrombocytopenia have been observed in less than 3 percent of treated patients. These changes are usually reversible within one week after drug discontinuation, but complete blood counts should be checked periodically in patients receiving more than seven days of therapy.

What happens if tigecycline is given with warfarin

Concurrent use can potentiate the anticoagulant effect of warfarin. INR monitoring is advised at the start of tigecycline therapy and again three to five days after any dosage change, because tigecycline inhibits CYP enzymes involved in warfarin metabolism.

When should tigecycline be avoided in pregnancy

Animal studies show fetal skeletal abnormalities and reduced fetal weight. Tigecycline is classified as pregnancy category D; it is contraindicated in the second and third trimesters unless no safer alternative exists.

Are there differences in side-effect profiles between brand-name and generic tigecycline

No clinically meaningful differences in adverse-event rates have been observed between the innovator product and approved generics. Bioequivalence studies submitted to the FDA confirm comparable pharmacokinetics and tolerability.

Source:
DrugPatentWatch.com [https://www.drugpatentwatch.com/drug/tigecycline]